Literature DB >> 15685691

Widespread and highly persistent gene transfer to the CNS by retrovirus vector in utero: implication for gene therapy to Krabbe disease.

Jin-Song Shen1, Xing-Li Meng, Takashi Yokoo, Ken Sakurai, Kazuhiko Watabe, Toya Ohashi, Yoshikatsu Eto.   

Abstract

BACKGROUND: Brain-directed prenatal gene therapy may benefit some lysosomal storage diseases that affect the central nervous system (CNS) before birth. Our previous study showed that intrauterine introduction of recombinant adenoviruses into cerebral ventricles results in efficient gene transfer to the CNS in the mouse. However, transgene expression decreased with time due to the non-integrative property of adenoviral vectors. In this study, in order to obtain permanent gene transduction, we investigated the feasibility of retrovirus-mediated in utero gene transduction.
METHODS: Concentrated retrovirus encoding the LacZ gene was injected into the cerebral ventricles of the embryos of normal and twitcher mice (a murine model of Krabbe disease) at embryonic day 12. The distribution and maintenance of the transgene expression in the recipient brain were analyzed histochemically, biochemically and by the quantitative polymerase chain reaction method pre- and postnatally.
RESULTS: Efficient and highly persistent gene transduction to the brain was achieved both in normal and the twitcher mouse. Transduced neurons, astrocytes and oligodendrocytes were distributed throughout the brain. The transduced LacZ gene, its transcript and protein expression in the brain were maintained for 14 months without decrement. In addition, gene transduction to multiple tissues other than the brain was also detected at low levels.
CONCLUSIONS: This study suggests that brain-directed in utero gene transfer using retrovirus vector may be beneficial to the treatment of lysosomal storage diseases with severe brain damage early in life, such as Krabbe disease. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685691     DOI: 10.1002/jgm.719

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

1.  An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice.

Authors:  Xiufang Pan; Scott A Sands; Yongping Yue; Keqing Zhang; Steven M LeVine; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-07-18       Impact factor: 5.695

2.  In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.

Authors:  L Chansel-Debordeaux; M Bourdenx; S Dovero; V Grouthier; N Dutheil; A Espana; L Groc; C Jimenez; E Bezard; B Dehay
Journal:  Gene Ther       Date:  2017-11-16       Impact factor: 5.250

3.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454

Review 4.  Experimental therapies in the murine model of globoid cell leukodystrophy.

Authors:  Yedda Li; Mark S Sands
Journal:  Pediatr Neurol       Date:  2014-08-08       Impact factor: 3.372

5.  Molecular beacon genotyping for globoid cell leukodystrophy from hair roots in the twitcher mouse and rhesus macaque.

Authors:  Kimberly A Terrell; Terri A Rasmussen; Cyndi Trygg; Bruce A Bunnell; Wayne R Buck
Journal:  J Neurosci Methods       Date:  2007-02-25       Impact factor: 2.390

6.  Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; Mark T Curtis; David A Wenger
Journal:  Mol Ther       Date:  2012-07-31       Impact factor: 11.454

7.  Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.

Authors:  Christopher J Folts; Nicole Scott-Hewitt; Christoph Pröschel; Margot Mayer-Pröschel; Mark Noble
Journal:  PLoS Biol       Date:  2016-12-15       Impact factor: 8.029

8.  Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?

Authors:  Mohammad A Rafi; Paola Luzi; David A Wenger
Journal:  Bioimpacts       Date:  2021-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.